MainStreet Investment Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,384 shares of the medical research company’s stock, valued at approximately $676,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Argent Trust Co boosted its holdings in Thermo Fisher Scientific by 0.3% during the 1st quarter. Argent Trust Co now owns 19,321 shares of the medical research company’s stock valued at $5,479,000 after acquiring an additional 62 shares during the period. Meitav Dash Investments Ltd. purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth $14,030,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Thermo Fisher Scientific by 1.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 82,451 shares of the medical research company’s stock worth $23,383,000 after buying an additional 1,406 shares during the period. Tredje AP fonden lifted its holdings in shares of Thermo Fisher Scientific by 6.4% in the 1st quarter. Tredje AP fonden now owns 33,995 shares of the medical research company’s stock worth $9,318,000 after buying an additional 2,054 shares during the period. Finally, National Asset Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 100.0% in the 1st quarter. National Asset Management Inc. now owns 8,338 shares of the medical research company’s stock worth $2,366,000 after buying an additional 4,169 shares during the period. Institutional investors own 88.68% of the company’s stock.
NYSE:TMO traded up $4.51 during mid-day trading on Friday, hitting $340.26. 1,097,619 shares of the company’s stock traded hands, compared to its average volume of 1,572,086. The company has a fifty day moving average of $324.75 and a 200 day moving average of $317.43. Thermo Fisher Scientific Inc. has a twelve month low of $250.21 and a twelve month high of $351.86. The company has a market capitalization of $132.60 billion, a P/E ratio of 37.31, a P/E/G ratio of 2.25 and a beta of 1.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.69 and a current ratio of 2.32.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 22nd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.79 by $0.15. Thermo Fisher Scientific had a return on equity of 17.25% and a net margin of 14.31%. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6.18 billion. During the same period in the prior year, the company posted $2.81 EPS. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, June 12th. Thermo Fisher Scientific’s dividend payout ratio is currently 7.13%.
Several equities research analysts have weighed in on the company. Argus reiterated a “positive” rating and issued a $370.00 target price on shares of Thermo Fisher Scientific in a report on Monday, February 24th. Needham & Company LLC upped their target price on Thermo Fisher Scientific from $341.00 to $383.00 in a report on Thursday, April 23rd. Citigroup upped their price objective on Thermo Fisher Scientific from $365.00 to $390.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $340.00 to $341.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. Finally, BTIG Research upped their price objective on Thermo Fisher Scientific from $342.00 to $372.00 and gave the stock an “in-line” rating in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $347.21.
In other news, COO Mark Stevenson sold 25,000 shares of the stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $328.03, for a total value of $8,200,750.00. Following the transaction, the chief operating officer now directly owns 73,538 shares of the company’s stock, valued at $24,122,670.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total value of $9,990,600.00. Following the completion of the transaction, the chief executive officer now directly owns 304,946 shares in the company, valued at $101,553,116.92. The disclosure for this sale can be found here. Corporate insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.